Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 18/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 16/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2481382 | 0.87 | ADH1C (0.40) | SLC6A2SLC6A4PIK3CDSLC6A3 | |
| SCHEMBL824136 | 0.87 | SLC6A2 (0.40) | SLC6A2SLC6A4PIK3CDSLC6A3 | |
| SCHEMBL9289972 | 0.83 | HTR1D (0.43) | SLC6A2SLC6A4PIK3CDSLC6A3 | |
| SCHEMBL150945 | 0.82 | SLC6A2 (0.41) | SLC6A2SLC6A4PIK3CDSLC6A3 | |
| SCHEMBL29952650 | 0.81 | SLC6A2 (0.37) | SLC6A2SLC6A4PIK3CDSLC6A3 | |
| SCHEMBL9281011 | 0.81 | SLC6A2 (0.37) | SLC6A2SLC6A4PIK3CDSLC6A3 | |
| SCHEMBL18523523 | 0.81 | SLC6A2 (0.34) | SLC6A2SLC6A4PIK3CDSLC6A3 | |
| SCHEMBL20780304 | 0.79 | SLC6A2 (0.39) | SLC6A2SLC6A4PIK3CDSLC6A3 | |
| SCHEMBL21047919 | 0.79 | SLC6A2 (0.39) | SLC6A2SLC6A4PIK3CDSLC6A3 | |
| SCHEMBL8045903 | 0.78 | SLC6A2 (0.33) | SLC6A2SLC6A4PIK3CDSLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11084800-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2021-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11084800-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | CFD, TFPI, CFH | SLC6A2 1380/4885SLC6A4 1399/4885PIK3CD 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.